五度妙笔
API商城
数据库CPIC 2026丨同写意与BioCentury达成合作协议
👆点击查看主席团阵容
旧金山&上海---2026年4月16日，在全球生物医药创新深度融合、跨境协作加速的时代浪潮下，中国生物医药创新领域的著名产业生态平台同写意（TONACEA）与全球生物医药商业情报与高管级会议的领导者BioCentury签署合作协议，以中美双引擎为核心，共建全球生物医药创新协作新生态。
双方同意，利用各自的平台资源和行业积累支持对方行业峰会的举办，包括品牌传播、嘉宾邀请以及会议推广等。具体而言，同写意邀请BioCentury作为智库平台支持首届大国新药全球会议的举办，同写意也将支持13th BioCentury-BayHelix China Healthcare Summit的举办。
对于此次合作，双方将依托各自平台优势与行业资源，相互支持对方旗舰行业峰会的举办，开展品牌联合传播、嘉宾邀约、会议推广等全方位协作。同写意特邀BioCentury作为智库平台，深度支持首届“大国新药”・全球会议（CPIC），借助其全球行业影响力与资源网络，通过官网联动、媒体互推、渠道共享等方式，扩大CPIC的国际曝光度与行业影响力，搭建中国生物医药创新走向全球、链接国际资源的重要桥梁。
同写意创始人、董事长程增江博士表示：此次与BioCentury的战略合作，是同写意“连接全球生态、赋能生物医药创新增长”使命的重要落地。双方将以顶级资源与专业能力，搭建中美生物医药核心合作枢纽，持续释放跨境协同价值，助力中国新药走向世界。
BioCentury 企业联盟与业务拓展负责人JoshuaBerlin表示：非常荣幸与中国生物医药创新核心平台同写意达成合作。依托 BioCentury 三十余年构建跨境网络的经验，我们将携手合作，助力连接西方与中国的生物医药领袖，加速药物研发和生物医药创新。
海外注册链接即将上线，敬请关注
The overseas registration link will be available soon. Stay tuned!
同写意是中国生物医药创新领域的著名生态平台，深耕中国新药创制20余年，已发展为推动中国医药创新力量的关键平台组织，成为链接跨国药企和本土创新的核心枢纽。
同写意聚跨国药企、Biotech公司、投资机构、科研院所及监管专家，构建起覆盖研发全链条的高端人脉网络与知识共享体系。业务涵盖行业峰会、技术论坛、企业定制培训、媒体传播及战略咨询，在北京、上海、苏州、广州、深圳等地设有分支机构，形成辐射全国的运营网络。
同写意微信公众号与视频号持续输出深度行业研究，观点被资本与媒体高频引用，成为业界公认的“官方信源”。平台联合发布的“华山奖”，树立中国创新药国际化标杆，推动本土企业走向世界舞台。
BioCentury 总部位于美国加利福尼亚州圣马特奥，是全球领先的生物医药行业情报平台。30 余年来, 它被生物医药行业的企业高管、投资人及政策制定者公认为行业黄金标准，致力于赋能下一代生物技术领军者。
作为多个国际顶级会议的主办方, 包括 BioCentury‑BayHelix 中国医疗健康峰会, BioCentury是跨境生物医药合作与创新生态体系中的的权威枢纽。
San Francisco & Shanghai–April 16, 2026
Against the backdrop of deepening integration and accelerating cross-border collaboration in global biopharmaceutical innovation, TONACEA, a leading industrial ecosystem platform dedicated to China’s biopharmaceutical innovation sector, has signed a cooperation agreement with BioCentury, the global leader in biopharmaceutical business intelligence and C-level conferences. Centered on a China‑U.S. dual engine, the two parties will jointly build a new ecosystem for global biopharmaceutical innovation and collaboration.
The parties agree to leverage their respective platform resources and industry expertise to support each other’s flagship industry summits, including brand promotion, guest invitations, and conference marketing. Specifically, TONACEA has invited BioCentury to serve as a think‑tank platform supporting the inaugural China Pharmaceutical Innovation Conference (CPIC). TONACEA will also support the 13th BioCentury-BayHelix China Healthcare Summit.
In this collaboration, both parties will draw on their respective platform strengths and industry resources to support one another’s flagship summits through comprehensive cooperation including joint brand communications, guest outreach, and global conference promotion. TONACEA has specially invited BioCentury to provide in‑depth support as a think‑tank platform for the inaugural “Great Power New Drugs” Global Conference (CPIC). Leveraging BioCentury’s global industry influence and resource network, the two sides will expand CPIC’s international visibility and industry impact through official website linkage, cross‑media promotion, and channel sharing, building a key bridge for China’s biopharmaceutical innovation to reach the world and connect with global resources.
Dr. Zengjiang Cheng, Founder and Chairman of TONACEA, stated:“This strategic partnership with BioCentury represents a major milestone in fulfilling TONACEA’s mission of ‘connecting the global ecosystem and empowering growth in biopharmaceutical innovation.’Together, we will deploy top‑tier resources and professional capabilities to build a core hub for China‑U.S. biopharmaceutical cooperation, continuously unlock cross‑border synergies, and help China’s innovative drugs go global.”
Mr. Joshua Berlin, Head of Corporate Alliances and Business Development for BioCentury, commented:“We are honored to partner with TONACEA, a central platform in China’s biopharmaceutical innovation ecosystem.Drawing on BioCentury’s 30-plus years of building cross-border networks, we will work together to help connect Western and China biopharma leaders to accelerate drug development and biopharma innovation.”
TONACEA is China’s premier ecosystem platform dedicated to biopharmaceutical innovation. With over two decades of deep-seated engagement in the biopharma innovation landscape, it has evolved into a pivotal powerhouse driving the nation’s pharmaceutical progress and a strategic nexus connecting multinational corporations (MNCs) with local innovators.
The platform converges a high-caliber network—comprising MNCs, biotechs, investment firms, research institutes, and regulatory bodies—to foster an integrated knowledge-sharing architecture across the entire R&D value chain.
TONACEA’s comprehensive service portfolio encompasses flagship industry summits, technical forums, bespoke corporate training, media dissemination, and strategic consultancy. With a robust operational footprint spanning Suzhou, Shanghai, Beijing, and Guangzhou, the platform projects strategic influence nationwide.
Through its influential media channels, TONACEA consistently delivers deep-dive industry intelligence, earning its reputation as a "trusted official source" frequently cited by the investment community and mainstream media. Furthermore, the co-initiated "Huashan Awards" have set the gold standard for the internationalization of Chinese innovation, empowering homegrown enterprises to command the global stage.
相关阅读：CPIC 2026丨同写意与GB·Partner正式签署战略合作协议
点击 "阅读原文"，立即访问CPIC官网
